178514 Pharma confronts the 21st century: Generic competition, compulsory licensing, and drug access and safety challenges from abroad

Wednesday, October 29, 2008: 11:06 AM

Jack Warren Salmon, PhD , Health Policy and Administration, University Of Illinois-Chicago, Chicago, IL
Meghana Aruru, PhD (cand) , College of Pharmacy / Pharmacy Administration, University of IIlinois at Chicago, Chicago, IL
The worldwide pharmaceutical market is undergoing very profound adjustments across this century. Multinational drug firms that have dominated the production of Western pharmaceuticals for the past three decades now face formidable new challenges. Their R&D has not been well sustained with breakthrough entities, and scores of branded drugs have been losing patent protection; these drugs were considered “blockbusters” in that their sales tallied in the billions each. Without patents, the rise of the generic drug industry chiefly based outside the Northern Hemisphere represents a major shift in revenues and easy profits. Moreover, the upgrading in technological capability and manufacturing might of various firms from Israel, India, China, Brazil, South Africa, and elsewhere allows these nations to better address the mounting unmet pharmaceutical needs across the developing world that the U.S. and European firms have historically neglected. Further specific challenges in trade policy (namely, compulsory licensing, national price setting, etc.) are directed at multinational Pharma firms, which, along with actions to address access and drug safety may delimit Western multinationals' previous power to shape the marketplace.

Learning Objectives:
1. To explore arising forces that are challenging Wester multinational drug firms this century 2. To delineate how such forces may offer new opportunities for advancement for generic firms in developing nations 3. To examine how trade policies and other actions by the developing world may delimit the past historical trajectory of the worldwide pharmaceutical sector and explore possible implications for drug access

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have been studying health system and pharmaceutical developments across the Pacific Rim for several years, being concerned with drug access and safety issues. No conflicts of interest to declare.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.